parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enriched in oligodendrocyte progenitor cells (2339 nCPM)	1.00
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 254	0.91
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 7353

receipt 7362: MMP16 in dopamine neurons, braak

power: full sample +0.24 (p 0.332, n 18), 95% CI -0.25 to +0.64. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.22 (p 0.389, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.243, n 18). could be the mix.
skeptic: leave-one-out range +0.15 to +0.39, sign flips 0; without severely affected donors +0.24 (p 0.332, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MMP16 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7361: MMP16 in oligodendrocytes, braak

power: full sample -0.07 (p 0.787, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.728, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.13 (p 0.609, n 18). could be the mix.
skeptic: leave-one-out range -0.17 to +0.06, sign flips 4; without severely affected donors -0.07 (p 0.787, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MMP16 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts